By Michael Brown, CP Op-Ed Contributor | Thursday, October 15, 2020
Have you heard the latest? Trump cannot be pro-life since he used and is promoting the anti-COVID drug Regeneron, which was allegedly developed with the help of fetal tissue. And pro-life organizations are being hypocritical by refusing to condemn the drug. Is there any truth to these charges?
As reported by the UK Metro, Trump faces hypocrisy allegations after it was revealed Regeneron is made from stem cells originally taken from an embryonic kidney. That kidney was taken during an elective abortion performed in the Netherlands during the 1970s.
More bluntly, the MIT Technology Review claimed, Trumps antibody treatment was tested using cells originally derived from an abortion.
The Trump administration has looked to curtail research with fetal cells. But when it was life or death for the president, no one objected.
As for pro-life organizations, a lengthy headline on Business Insider stated, Antiabortion groups say they stand behind Trump's use of a drug tested on cells derived from an aborted fetus because the president was not involved with that abortion.
How should pro-life Trump voters respond to these concerns?
Lets say that Regeneron was actually developed with the help of fetal tissue. Does anyone actually think that doctors came to Trump and said, Mr. President, we have an experimental drug that was tested and developed using tissue from an aborted baby from the 1970s. How do you feel about using this?
Only the most hardened anti-Trumper could imagine such a scenario. In the world of reality, the very thought of it is absurd. And, even if the fetal tissue charges are true, who knew about this? Was this something that any of the doctors would have been aware of? I very seriously doubt it, especially when, as we shall see, Regeneron itself denies the charge.
Join over 250,000 others to get the top stories curated daily, plus special offers!
Join over 250,000 others to get the top stories curated daily, plus special offers!
It is therefore completely ridiculous to claim that Trump is being hypocritical in using Regeneron, as if he knew the alleged history of the drug.
But that leads us back to the big question: Did Regeneron use fetal tissue from a baby aborted in the 1970s?
Another headline on Business Insider stated, One of Trump's COVID-19 treatments was developed using tissue that originally came from an abortion. He's tried to ban this kind of research.
This is being widely reported as established fact. But is it true?
In an official statement for the pro-life Charlotte Lozier Institute, David Prentice, Ph.D. and Tara Sander Lee, Ph.D., wrote:
The Regeneron therapy given to the president was made in Velocimmune humanized mice, a novel platform that uses genetically modifiedmouse embryonic stem (ES)cells to generate antibodies describedhereandhere.Development of Regenerons antibody cocktail is detailed in the journalScience, describing how they identified their antibodies made from Velocimmune miceandblood from recovered patientspreviously infected with SARS-CoV-2.The final antibody pair used in theREGN-COV2 therapycocktail was then produced inChinese hamster ovary (CHO) cells.Results from Regenerons REGN-COV2 clinical trials to treat COVID-19 patients are reportedhere.
Mouseembryonic stem cells and genetic modifications to make such mice date back to 1981, have been extensively studied, and were instrumental in the discovery of induced pluripotent stem (iPS) cells, another fully ethical alternative to fetal material, as discussed in thisNaturereview.iPSCs are much easier to use thanhuman embryonic stem cells,more flexible in their uses, and are not ethically controversial. No one has ever advocated against using mouse embryonic stem cells for development of therapies only against destruction of human lives.
In a statement made to The Christian Post, Alexandra Bowie, a spokesperson for Regeneron, explained, We did not use human stem cells or human embryonic stem cells in the development of REGN-COV2. We did use the HEK293T cell line to test our antibodies ability to neutralize the SARS-CoV-2 virus (they were used to make pseudovirus that looks like the Spike protein).
HEK293s are considered immortalized cells and are a common and widespread tool in research labs. The cell line was originally derived by adenovirus transformation of human embryonic kidney cells in 1977.
After this, it was further transformed at Stanford in the 80s with SV40 T-antigen (hence the T). HEK293T wasnt used in any other way and fetal tissue was not used in this research.
Im not a medical doctor or a scientist, but it seems clear from these descriptions (and from what I could glean from Regenerons technical article published in the journal Science, also cited above) that there is hardly a direct connection between the drug and an aborted baby.
Still, there is so much misinformation going viral online that Dr. Tara Lee started a Twitter account just to rebut the misconceptions. (Lees Twitter bio identifies her as Researcher, Clinical Scientist, Science Policy Advisor. PhD. Senior Fellow & Director of Life Sciences @lozierinstitute. For LIFE in this world and the next.)
She summarized the evidence in simple and clear terms: NO human embryonic stem cells or human fetal tissue were used to produce the treatments President Trump received period.
So, Regeneron denies that it used embryonic cells and other scientists deny it. This completely undermines the charge that pro-life groups are being hypocritical for not condemning the use of the drug (and the presidents promotion of it).
That being said, some pro-life groups have, in fact, opined that, even if testing for the drug could be traced back to an abortion in the 1970s, Trump had nothing to do with any of this and is therefore not being hypocritical in promoting the drug.
Is there some hypocrisy in this response?
Thats a fair question, and its the type of question that ethicists debate. If you could save the lives of many people using a drug that was developed with the help of aborted fetal cells, is that justifiable?
My answer to those accusing the president with hypocrisy is threefold. First, as stated here, its unlikely in the extreme he had any idea of the alleged abortion connection. Second, scientists from Regeneron deny any connection to human fetal cells, and Trump would presumably take them at their word. Third, if Regeneron had been developed with the help of an aborted baby, there would then be a serious ethical debate as to its use.
Still, with all that being said, it is grasping at straws to question the pro-life commitment of these organizations (along with that of President Trump). Thats because we are comparing the willful killing of more than 60 million babies in the womb, often out of convenience, with the possible, distant connection of a life-saving drug to a baby aborted in the 1970s. Who would seriously make such a comparison?
When it comes to the question of the benefit of embryonic cells in the development of medical cures, Dr. Lee noted that, Fetal tissue from aborted babies is not required for medical advancements. After 100+ years of research, no therapies have been developed that needed aborted fetal tissue to begin with. Newer & better ethical alternatives are available & being used now to make humanized mice.
There is, therefore, no justification for using embryonic fetus cells in medical research, and the Regeneron drug does not contradict this at all.
Of course, as readers here know well, I have no problem identifying President Trumps many, evident shortcomings, some of which can be quite destructive. And I continue to shake my head over some of the things he says.
But to call him a hypocrite or to question his pro-life commitment because he used Regeneron is to reveal ones anti-Trump animus. It indicts the accuser far more than it indicts the accused.
Join over 250,000 others to get the top stories curated daily, plus special offers!
Join over 250,000 others to get the top stories curated daily, plus special offers!
Dr. Michael Brown(www.askdrbrown.org) is the host of the nationally syndicatedLine of Fireradio program. His latest book isEvangelicals at the Crossroads: Will We Pass the Trump Test?Connect with him onFacebook,Twitter, orYouTube.
More:
Regeneron, Trump, and the alleged hypocrisy of the pro-life movement - Christian Post
- Detection of biomagnetic signals from induced pluripotent stem cell-derived cardiomyocytes using deep learning with ... - Nature.com - April 1st, 2024
- Researchers discover new microRNA-regulated pathway to boost iPS cell-derived platelet production - Phys.org - March 30th, 2024
- Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks - Nature.com - March 28th, 2024
- Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock - The Scientist - March 13th, 2024
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy - Nature.com - March 3rd, 2024
- Breaking through new research barriers with iPSC technology - News-Medical.Net - February 15th, 2024
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 12th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 12th, 2024
- Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for ... - Nature.com - December 23rd, 2023
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming - Nature.com - December 15th, 2023
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 13th, 2023
- CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes ... - Nature.com - December 7th, 2023
- World Hindu Congress 2023: Know all about the sessions and speakers - Organiser - November 23rd, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS ... - Business Wire - November 21st, 2023
- Efficient protocol for the differentiation of kidney podocytes from ... - Nature.com - November 17th, 2023
- Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com - November 17th, 2023
- Study reveals the critical role of microglia in human brain development - Medical Xpress - November 15th, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through... - November 15th, 2023
- Who are the leading innovators in iPSCs for the pharmaceutical ... - Pharmaceutical Technology - November 7th, 2023
- Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous... - November 5th, 2023
- Systematic differences in discovery of genetic effects on gene ... - Nature.com - October 21st, 2023
- Pairwise biosynthesis of ion channels stabilizes excitability and ... - pnas.org - October 11th, 2023
- Scientists find multitude of genes associated with autism - The Statesman - October 9th, 2023
- Stem Cell Banking Market is Expected to Reach USD 16,474.30 ... - Digital Journal - October 7th, 2023
- Probing the individuality of cells and molecules - Open Access Government - October 5th, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Manchestertimes - October 3rd, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Business Wire - September 29th, 2023
- Less Funding to More Researchers Gets Nobel-level Results, Study ... - The Japan News - September 27th, 2023
- Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for ... - OncLive - September 20th, 2023
- DKMS BMST Foundation India and Kokilaben Hospital unite to spread awareness about the Importance of Stem Cell Donation on World Marrow Donor Day - APN... - September 18th, 2023
- Vitamin B6 is governed by the local compartmentalization of ... - Science - September 14th, 2023
- Dolly the sheep creator Ian Wilmut dies aged 79 - BBC - September 14th, 2023
- Scientist who created Dolly the sheep dies aged 79: Professor Sir Ian Wilmut passes away five years after reve - Daily Mail - September 11th, 2023
- The global kits market is expected to grow at a CAGR of 7.4% from ... - Digital Journal - September 8th, 2023
- Eterna Therapeutics Announces Initiation of Development Activities ... - PipelineReview.com - September 8th, 2023
- Tokyo: 100 Years of Urban Regeneration / Tokyo's Nihonbashi Area ... - The Japan News - August 31st, 2023
- Transcriptome-based prediction of drugs, inhibiting ... - Nature.com - August 30th, 2023
- From the birds and the bees to IVG - The Gauntlet - August 26th, 2023
- Breakthrough creates stem cells without any memories - Freethink - August 26th, 2023
- Aging impairs the neurovascular interface in the heart - Science - August 26th, 2023
- For This Venture Capitalist, Research on Aging Is Personal; 'Bob ... - The Wall Street Journal - August 22nd, 2023
- Unleashing Potential: Illuminating the Future of Healthcare through Revolutionary Induced Pluripotent Stem Cel - openPR - August 18th, 2023
- A 'memory wipe' for stem cells may be the key to better therapies - The Conversation - August 16th, 2023
- Erasing epigenetic 'memory' to improve the quality of stem cells - FierceBiotech - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Business Wire - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Valdosta Daily Times - August 11th, 2023
- Advancing Clinical Trials with iPSC-Derived Liver Organoids - Microbioz India - August 11th, 2023
- Activation of cAMP (EPAC2) signaling pathway promotes hepatocyte ... - Nature.com - August 1st, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapys Ability to Create New Skeletal... - July 30th, 2023
- Femtech in Japan: An Industry on the Rise - Femtech Insider - July 28th, 2023
- Association between enhanced carbonyl stress and decreased ... - Nature.com - July 28th, 2023
- Defects in early synaptic formation and neuronal function in Prader ... - Nature.com - July 27th, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of ... - Business Wire - July 25th, 2023
- Cure to Autism and Alzheimer's May Be in Space, Says 1st Brazilian Scientist who Will Be on The ISS - Folha de S.Paulo - July 25th, 2023
- Futurama's Resurrection Ruins The Perfect Ending (& Shows Must ... - Looper - July 25th, 2023
- University Of Massachusetts Amherst's Team Bags Honour Of 2023 Armstrong Fund For Science Award - India Education Diary - July 20th, 2023
- Scientists working on IVG, a new reproductive method that can make human babies in labs - IndiaTimes - July 19th, 2023
- Co-transplantation of autologous Treg cells in a cell therapy for ... - Nature.com - July 13th, 2023
- Magic Valley and Biocellion Join Forces to Improve Bioreactor Tech ... - vegconomist - the vegan business magazine - July 13th, 2023
- IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ... - Tullahoma News and Guardian - July 10th, 2023
- Hitachi : forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT - Marketscreener.com - July 6th, 2023
- Cell therapy limitations with iPS-based multi-cell therapeutics - Drug Target Review - July 6th, 2023
- Remembering Dolly- The Clone Sheep On Her Birth Anniversary - Free Press Journal - July 4th, 2023
- Labs and Translational Research - UMass Medical School - June 28th, 2023
- Cellusion raises 2.83B series C round to progress iPS cell-derived ... - BioWorld Online - June 14th, 2023
- Japan-based Fujifilm introduces first-of-its-kind human iPSC-derived ... - BSA bureau - June 6th, 2023
- ALS: Parkinson's drug ropinirole may be an effective treatment - Medical News Today - June 4th, 2023
- Scientists predict lab-grown babies in five years - Kidspot - June 4th, 2023
- Lab-grown babies could become a reality within five years - Earth.com - May 26th, 2023
- Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month - ZAWYA - May 24th, 2023
- Long-Awaited Ax-2 Mission Launches, Heads to Space Station - AmericaSpace - May 22nd, 2023
- Eterna Therapeutics and Factor Bioscience Announce New Data on ... - GlobeNewswire - May 17th, 2023
- Research Assistant job with UNITED ARAB EMIRATES ... - Times Higher Education - May 10th, 2023
- Regulation of synaptic connectivity in schizophrenia spectrum by ... - Nature.com - April 29th, 2023
- Researchers Discover Key Role of Glucose in Brain Activity - Laboratory Equipment - April 25th, 2023
- Structure of Huntington's Protein Revealed - Technology Networks - April 21st, 2023
- Study of brain immune cell infection may explain long COVID ... - NHK WORLD - April 19th, 2023
- The Mechanism That Regulates Activity of Memory Gene - Neuroscience News - April 19th, 2023
- The IPO Buzz: CytoMed Therapeutics Prices its Micro-Cap IPO at ... - IPOScoop - April 19th, 2023
- Macomics Presents its ENIGMAC Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR - Yahoo Finance - April 19th, 2023
Recent Comments